



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, February 22, 2022

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), is hereby reported the following:

OTHER RELEVANT INFORMATION

We hereby inform that Pharma Mar, S.A. will host a key opinion leader (KOL) webinar addressed to investors and analysts, entitled “*Small Cell Lung Cancer: Today, until Tomorrow, US & EU*” on Wednesday, March 9th, 2022 at 1pm EST / 7pm CET.

The webinar will feature presentations by Key Opinion Leaders (KOLs) Professor Dr. Benjamin Besse from Institut Gustave Roussy, Villejuif, France and Dr. Jacob Sands from Dana Farber Cancer Institute, Boston. They will discuss the latest research in SCLC and the current landscape in various lines of treatment, including the first-line and relapsed settings. They will also discuss the various unmet medical needs of patients and physicians and present their view on the future treatment paradigm.

The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain), +1 646 664 1960 (from USA or Canada) or +44 20 3936 2999 (other countries). Participant access code: 620352.

The teleconference will be available on PharmaMar's website by visiting the [Events Calendar](#) section of the company's website at www.pharmamar.com

Please find attached press release that will be distributed to the media today.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar to Host Key Opinion Leader Webinar on Small Cell Lung Cancer

“Small Cell Lung Cancer: Today, until Tomorrow, US & EU”

Wednesday, March 9th 2022 - 1 pm EST / 7 pm CET

Featuring Dr. Jacob Sands from Dana Farber Cancer Institute, Boston and Dr. Benjamin Besse from Institut Gustave Roussy, Villejuif, France

Madrid, February 22nd, 2022.- PharmaMar (MSE: PHM) today announced that it will host a key opinion leader (KOL) webinar addressed to investors and analysts, entitled “*Small Cell Lung Cancer: Today, until Tomorrow, US & EU*” on Wednesday, March 9th at 1pm EST/7pm CET.

The webinar will feature presentations by Key Opinion Leaders (KOLs) Professor Dr. Benjamin Besse from Institut Gustave Roussy, Villejuif, France and Dr. Jacob Sands from Dana Farber Cancer Institute, Boston. They will discuss the latest research in SCLC and the current landscape in various lines of treatment, including the first-line and relapsed settings. They will also discuss the various unmet medical needs of patients and physicians and present their view on the future treatment paradigm.

This event follows the initiation by PharmaMar of a global randomized phase III study of Zepzelca[®] (lurbinectedin) monotherapy or in combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) (NCT05153239)¹. This trial is expected to serve in a confirmatory capacity in the US following lurbinectedin’s accelerated FDA approval in 2020, as well as a registrational capacity for EMA and other regulatory bodies.

In addition, North America partner Jazz Pharmaceuticals along with its partner Roche Pharmaceuticals initiated a Phase III study assessing the safety and efficacy of lurbinectedin as a first-line maintenance treatment in Small Cell Lung Cancer (SCLC)

¹ ClinicalTrials.gov Identifier: NCT05153239:

<https://clinicaltrials.gov/ct2/show/NCT05153239?term=NCT05153239&draw=2&rank=1>



(NCT05091567)². If successful, the trial could support an FDA supplemental new drug application, and potentially allow PharmaMar to submit a dossier for registration to the European Medicines Agency. PharmaMar holds full commercial rights for lurbinectedin in Europe and most territories outside the United States and Canada.

The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain), +1 646 664 1960 (from USA or Canada) or +44 20 3936 2999 (other countries). Participant access code: 620352.

The teleconference will be available on PharmaMar's website by visiting the [Events Calendar](#) section of the company's website at www.pharmamar.com

A recording of the webcast will be made available to accredited investors. To request a link, please feel free to reach out to investorrelations@pharmamar.com.

About Professor Dr. Benjamin Besse

Dr. Benjamin Besse is Professor of Medical Oncology at Paris-Saclay University, Orsay, France and a full-time cancer specialist at Gustave Roussy Cancer Campus, Villejuif, France. Currently, Dr. Besse is Head of the Cancer Medicine Department at Gustave Roussy Cancer Campus and Chair of the EORTC Lung Group. He coordinates the French network for thymic malignancy. His main research interests are application of molecular abnormalities to personalize treatment, circulating biomarkers, early drug development in thoracic tumors and thymic malignancies. He has authored/co-authored more than 250 peer-reviewed papers.

About Dr. Jacob Sands

Dr. Jacob Sands received his MD from the University of Cincinnati in 2005. He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis. He joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017. His research focuses on improved diagnostics and treatments for small cell lung cancer as well as improving lung screening and assisting in the development of lung screening programs throughout the country.

Legal warning

² ClinicalTrials.gov Identifier: NCT05091567:
<https://clinicaltrials.gov/ct2/show/NCT05091567?term=NCT05091567&draw=2&rank=1>



This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and PM14. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

About lurbinectedin

Lurbinectedin (Zepzelca®), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt *Ecteinacidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com. Mobile: +34 669 47 18 03

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com